PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study

被引：1

作者：

Rubio-Viqueira, Belen ^{[1
]}

Tarruella, Margarita Majem ^{[2
]}

Lazaro, Martin ^{[3
]}

Estevez, Sergio Vazquez ^{[4
]}

Cordoba-Ortega, Juan Felipe ^{[5
]}

Maiques, Inmaculada Maestu ^{[6
]}

Gonzalez, Jorge Garcia ^{[7
]}

Cordellat, Ana Blasco ^{[8
]}

Valdivia-Bautista, Javier ^{[9
]}

Arenas, Carmen Gonzalez ^{[10
]}

Sanchez Torres, Jose Miguel ^{[11
]}

机构：

[1] Quironsalud Madrid Hosp, Dept Med Oncol, Madrid, Spain

[2] Santa Creu & St Pau Hosp, Dept Med Oncol, Barcelona 08041, Spain

[3] Alvaro Cunqueiro Univ Hosp, Dept Med Oncol, Vigo 36213, Spain

[4] Lucus Augusti Univ Hosp, Dept Med Oncol, Lugo 27003, Spain

[5] Arnau de Vilanova Univ Hosp, Dept Med Oncol, Lleida 46015, Spain

[6] Doctor Peset Univ Hosp, Dept Med Oncol, Valencia 46017, Spain

[7] Univ Clin Hosp Santiago Compostela, Dept Med Oncol, A Couruna 15706, Spain

[8] CIBERONC, Hosp Gen Univ Valencia, Dept Med Oncol, Valencia 46014, Spain

[9] Virgen Nieves Univ Hosp, Dept Med Oncol, Granada 18014, Spain

[10] MSD, Dept Med Oncol, Madrid 28027, Spain

[11] La Princesa Univ Hosp, Dept Med Oncol, Madrid 28006, Spain

来源：

LUNG CANCER MANAGEMENT | 2021年 / 10卷 / 04期

关键词：

advanced; first-line treatment; immunotherapy; metastatic; NSCLC; PD-L1; expression; OPEN-LABEL; PEMBROLIZUMAB; CHEMOTHERAPY; MULTICENTER; THERAPY; PHASE-3;

D O I：

10.2217/lmt-2021-0008

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Aim: To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain. Methods: Multicenter, retrospective study. Results: Among 297 evaluated patients, 89.2% received systemic treatment for stage IV disease, of whom 53.6% received platinum doublet therapy, 26.8% immunotherapy as monotherapy and 14.7% immunotherapy + chemotherapy, with 9.4% receiving treatment as part of a clinical trial. Treatment was initiated 1 month after histological diagnosis, with PD-L1 test results available in most cases (92.6%). PD-L1 testing was performed in 287 patients, 95.1% by in-house tests, mostly with the 22C3 pharmDx assay. The factor most strongly associated with treatment selection was, as expected, the expression of PD-L1. Conclusion: PD-L1 testing is implemented in clinical practice and seems to guide treatment decisions in patients with NSCLC in Spain.

引用

页数：15

共 50 条

[31] Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
Seto, Takashi
Nosaki, Kaname
Shimokawa, Mototsugu
Toyozawa, Ryo
Sugawara, Shunichi
Hayashi, Hidetoshi
Murakami, Haruyasu
Kato, Terufumi
Niho, Seiji
Saka, Hideo
Oki, Masahide
Yoshioka, Hiroshige
Okamoto, Isamu
Daga, Haruko
Azuma, Koichi
Tanaka, Hiroshi
Nishino, Kazumi
Tohnai, Rie
Yamamoto, Nobuyuki
Nakagawa, Kazuhiko
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
[32] Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Wang, Xueping
Guo, Zhixing
Wu, Xingping
Chen, Da
Wang, Fang
Yang, Lewei
Luo, Min
Wu, Shaocong
Yang, Chuan
Huang, Lamei
Fu, Liwu
IMMUNOTARGETS AND THERAPY, 2023, 12 : 1 - 16
[33] The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma
Wang, H.
Agulnik, J.
Kasymjanova, G.
Fiset, P. O.
Camilleri-Broet, S.
Redpath, M.
Cohen, V
Small, D.
Pepe, C.
Sakr, L.
Spatz, A.
LUNG CANCER, 2019, 132 : 36 - 38
[34] Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
Park, Song Ee
Lee, Se Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Park, Keunchil
Sun, Jong-Mu
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (01) : 106 - 111
[35] PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer
Wang, Gang
Ionescu, Diana N.
Lee, Cheng-Han
Hiruki, Tadaaki
Myers, Renelle
Shaipanich, Tawimas
Lam, Stephen
Melosky, Barbara
Zhou, Chen
LUNG CANCER, 2019, 136 : 1 - 5
[36] Efficacy and safety of the PD-1/PD-L1 in metastasic non-small cell lung cancer (NSCLC)
Gonzalez-Velez, Abel
Pino-Villareal, Luis E.
Barrera-Barinas, Alexander
Castillo-Niuman, Andrea
Tolosa-Perez, Erica N.
Castelblanco, Diana, I
Pinzon-Florez, Carlos E.
Yomayusa, Nancy
GACETA MEXICANA DE ONCOLOGIA, 2021, 20 (03): : 111 - 123
[37] Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
Pagni, Fabio
Malapelle, Umberto
Doglioni, Claudio
Fontanini, Gabriella
Fraggetta, Filippo
Graziano, Paolo
Marchetti, Antonio
Rocco, Elena Guerini
Pisapia, Pasquale
Vigliar, Elena V.
Buttitta, Fiamma
Jaconi, Marta
Fusco, Nicola
Barberis, Massimo
Troncone, Giancarlo
CANCERS, 2020, 12 (07) : 1 - 16
[38] Targeting PD-L1 for non-small-cell lung cancer
Feld, Emily
Horn, Leora
IMMUNOTHERAPY, 2016, 8 (06) : 747 - 758
[39] The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Qu, Jingjing
Mei, Quanhui
Liu, Li
Cheng, Tianli
Wang, Peng
Chen, Lijun
Zhou, Jianying
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[40] Durvalumab for the treatment of PD-L1 non-small cell lung cancer
Naito, Tomoyuki
Shiraishi, Hideaki
Fujiwara, Yutaka
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (02): : 95 - 105

← 1 2 3 4 5 →